Physician profile
William L Guy
NPI 1295748101
$562,033.72
in general payments reported to CMS, 2019-2025
32 companies · $169K in 2025
The $169K reported for 2025 was more than what 99% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $66K · 2020: $20K · 2021: $42K · 2022: $61K · 2023: $70K · 2024: $134K · 2025: $169K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $272K · Travel and Lodging: $44K · Consulting Fee: $32K · Food and Beverage: $12K · Honoraria: $12K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $1,500 · Education: $7.51.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $271,688.15 |
| Travel and Lodging | $43,504.79 |
| Consulting Fee | $32,110.00 |
| Food and Beverage | $12,260.65 |
| Honoraria | $11,800.00 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $1,500.00 |
| Education | $7.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $272,915.60 | 2020-2025 | Caplyta |
| Teva Pharmaceuticals USA, INC. | $105,232.28 | 2019-2025 | Austedo Xr, Austedo Xr, Uzedy |
| Otsuka America Pharmaceutical, INC. | $74,610.78 | 2019-2025 | Rexulti, Abilify Maintena, Abilify Mycite |
| Axsome Therapeutics, INC. | $45,818.42 | 2023-2025 | Auvelity |
| Alkermes, INC. | $32,934.43 | 2019-2025 | Aristada, Lybalvi |
| Vanda Pharmaceuticals INC. | $18,638.69 | 2019-2025 | Fanapt |
| Sunovion Pharmaceuticals INC. | $7,722.63 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $578.49 | 2019-2023 | Spravato |
| Corium, LLC | $463.90 | 2022-2024 | Azstarys |
| Takeda Pharmaceuticals U.S.A., INC. | $461.28 | 2019-2024 | Trintellix |
| Neurocrine Biosciences, INC. | $387.85 | 2019-2024 | Ingrezza |
| Avanir Pharmaceuticals, INC. | $373.28 | 2019-2022 | |
| Idorsia Pharmaceuticals US INC | $274.42 | 2022-2024 | Quviviq |
| Lundbeck LLC | $238.22 | 2019-2024 | Rexulti |
| Abbvie INC. | $215.58 | 2021-2024 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Livanova USA, INC. | $197.88 | 2021 | |
| Neuronetics, INC. | $153.25 | 2020-2021 | |
| Indivior INC. | $149.59 | 2019-2023 | Perseris |
| Allergan, INC. | $132.91 | 2019-2020 | |
| Tris Pharma INC | $83.35 | 2022-2024 | Dyanavel Xr |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $80.61 | 2019 | |
| Merck Sharp & Dohme LLC | $67.21 | 2022-2023 | Belsomra |
| Bausch Health US, LLC | $66.23 | 2022-2023 | Aplenzin, Wellbutrin |
| E.R. Squibb & Sons, L.L.C. | $43.53 | 2024-2025 | Cobenfy |
| Supernus Pharmaceuticals, INC. | $38.39 | 2023-2024 | Qelbree, Qelbree |
| Eisai INC. | $33.89 | 2021-2022 | |
| Noven Therapeutics, LLC | $32.58 | 2024 | Xelstrym, Secuado |
| Ironshore Pharmaceuticals INC. | $18.78 | 2019 | |
| Shire North American Group INC | $18.50 | 2019 | |
| Brainsway USA INC | $17.64 | 2022 | |
| Neos Therapeutics, LP | $16.79 | 2019 | |
| Owp Pharmaceuticals, INC. | $16.74 | 2020-2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Guy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.